The Global Pyridoxine Hydrochloride (Vitamin B6) Market Is Expected To Witness High Growth Owing To the Increasing Cases of Liver and Kidney Issues in the World

Pyridoxine Hydrochloride (Vitamin B6) Market, By Grade (Food Grade and Non-food Grade), By End-use Industry (Food & Beverages, Animal Feed, Pharmaceuticals, and Personal Care), By Region (North America, South America, Europe, Asia Pacific, and the Middle East & Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2025.

Competitive Landscape:

Acebright Pharmaceuticals Group, Huazhong Pharmaceutical, Nanjing Pharmaceutical Factory Co. Ltd., Shanghai Hegno Pharmaceutical Holding, Royal DSM, BASF, Now Foods, and Jiangxi Tianxin Pharmaceuticals Co. Ltd.

Request a sample copy of the report to understand the complete report:
https://www.coherentmarketinsights.com/insight/request-sample/2133

Market Overview:

Pyridoxine hydrochloride (vitamin B6) is one of the most important B vitamins, and hence an extremely vital vitamin to the health of most people. Pyridoxine hydrochloride (vitamin B6) has proven to lower homocysteine levels in the bloodstream, which may help prevent heart disease. Studies have also indicated that increasing the intake of pyridoxine hydrochloride (vitamin B6) can help lower the risks for cardiovascular disease, certain cancers, and stroke. More recent studies indicate that people who ingest a high amount of pyridoxine hydrochloride (vitamin B6) have a reduced risk for degenerative eye diseases like glaucoma. However, most doctors recommend that people should not exceed the suggested daily allowance of folic acid, because too much of it can also cause folic acid insufficiency, leading to vision loss and other serious problems. For this reason, pregnant women, people who are breastfeeding, or children younger than 2 should avoid taking pyridoxine hydrochloride (vitamin B6), as it can harm their delicate body systems.

 Key Market Drivers:

Vitamin b6 deficiency is observed mostly in patients suffering from autoimmune diseases, kidney diseases, and liver diseases. Hence the increasing prevalence of these diseases is expected to augment the growth of the global pyridoxine hydrochloride (vitamin B6) market. For instance, according to World Gastroenterology Organization, more than 50 million individuals in the world suffer from chronic liver issues. Pyridoxine hydrochloride (vitamin B6) is available in tablet and capsule forms, and many popular vitamin supplement products. It is a relatively easy vitamin to digest, so it usually comes as a complex compound. . For those with chronic illnesses, or who have a pre-existing condition, it is best to consult a physician before taking any vitamin. Hence the increasing launch of several new products by key market players is expected to enhance the growth of the global pyridoxine hydrochloride (vitamin B6) market.

Covid-19 Impact Analysis:

Increasing COVID-19 positive cases in the world is the main factor that posed a challenge to the growth of the global pyridoxine hydrochloride (vitamin B6) market. For instance, according to Our World in Data, by August 2021, the 7 day average of COVID-19 cases have been around 607,993 in the world. Moreover, increasing lockdown restrictions have also affected the market growth negatively.

Key Takeaways:

• The global pyridoxine hydrochloride (vitamin B6) market is assessed to increase at a CAGR of 8.9%, owing to increasing cases of autoimmune disorders in the world. For instance, according to the National Stem Cell Foundation, around 4% of the world is suffering from 80 different autoimmune diseases.
• North America is expected to hold a major share of the global pyridoxine hydrochloride (vitamin B6) market, owing to the increasing product launches by several key market players in the region. For instance, in April 2018 Duchesnay USA announced the launch of Bonjesta, which is a doxylamine succinate – pyridoxine hydrochloride medication in the U.S. region.
• Asia Pacific is estimated to witness high growth in the global pyridoxine hydrochloride (vitamin B6) market, owing to increasing cases of liver and kidney issues in the region. For instance, according to Karger Publishers, the estimated prevalence of chronic kidney disease is around 800 per million population.

 Go Through Our Trusted Clients List:
https://www.coherentmarketinsights.com/trusted-by